Carnitine biosynthesis pathway (null)

The **carnitine biosynthesis pathway** is a multi-step metabolic process that enables the endogenous production of L-carnitine, a molecule essential for the transport of long-chain fatty acids into mitochondria for β-oxidation and ATP generation. In humans and other animals, L-carnitine is obtained both from the diet and through biosynthesis. The pathway is highly conserved across many eukaryotes and involves at least four key enzymatic steps: (1) *N*^ε^-trimethyllysine hydroxylase (TMLH), (2) 3-hydroxy-*N*^ε^-trimethyllysine aldolase, (3) 4-*N*-trimethylaminobutyraldehyde dehydrogenase, and (4) γ-butyrobetaine hydroxylase (BBH). These enzymes convert *N*^ε^-trimethyllysine, mainly derived from protein degradation, into L-carnitine[3][5][7]. Carnitine biosynthesis takes place primarily in the liver, kidney, and to some degree in the brain and gut epithelium[4][7]. Disturbances in this pathway can result in primary or secondary carnitine deficiency, affecting lipid metabolism, energy balance, and leading to various disease phenotypes. While modulation of related transporters and enzymes may be of clinical therapeutic interest, the **pathway itself is not a single druggable target but a series of enzyme-catalyzed reactions**[1][3]. Therapies more commonly target specific enzymes (such as γ-butyrobetaine hydroxylase) or transporters, not the pathway as a whole. Note: There is something incorrect with considering "Carnitine biosynthesis pathway" as a drug target per se. It is a biochemical pathway, not a specific molecular target; identifying specific enzymes or transporters in this pathway is required for drug targeting or structured database purposes.

Other names

L-carnitine biosynthetic pathwayL-carnitine synthesisCarnitine synthesis

null